THE EFFICACY OF INFLUENZA VACCINE IN ELDERLY PERSONS - A METAANALYSIS AND REVIEW OF THE LITERATURE

被引:846
作者
GROSS, PA
HERMOGENES, AW
SACKS, HS
LAU, J
LEVANDOWSKI, RA
机构
[1] SHEEHAN MEM HOSP, BUFFALO, NY 14203 USA
[2] MT SINAI MED CTR, CLIN TRIALS UNIT, NEW YORK, NY 10029 USA
[3] TUFTS NEW ENGLAND MED CTR, DIV CLIN CARE RES, BOSTON, MA 02111 USA
[4] CTR BIOL EVALUAT & RES, DIV VIRAL PROD, ROCKVILLE, MD 20892 USA
[5] UNIV MED & DENT NEW JERSEY, NEWARK, DE USA
[6] US FDA, BETHESDA, MD USA
关键词
D O I
10.7326/0003-4819-123-7-199510010-00008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To quantify the protective efficacy of influenza vaccine in elderly persons. Data Sources: A MEDLINE search was done using the index terms influenza vaccine, vaccine efficacy, elderly, mortality, hospitalized, and pneumonia. Appropriate references in the initially selected articles were also reviewed. Study Selection: Only cohort observational studies with mortality assessment were included in the metaanalysis. In addition, 3 recent case-control studies, 2 cost-effectiveness studies, and 1 randomized, double-blind, placebo-controlled trial were reviewed. Data Extraction: Vaccine and epidemic virus strains, age and sex of patients, severity of illness, patient status, and study design were recorded. Upper respiratory illness, hospitalization, pneumonia, and mortality were used as outcome measures. Data Synthesis: In a meta-analysis of 20 cohort studies, the pooled estimates of vaccine efficacy (1 odds ratio) were 56% (95% CI, 39% to 68%) for preventing respiratory illness, 53% (CI, 35% to 66%) for preventing pneumonia, 50% (CI, 28% to 65%) for preventing hospitalization, and 68% (CI, 56% to 76%) for preventing death. Vaccine efficacy in the case-control studies ranged from 32% to 45% for preventing hospitalization for pneumonia, from 31% to 65% for preventing hospital deaths from pneumonia and influenza, from 43% to 50% for preventing hospital deaths from all respiratory conditions, and from 27% to 30% for preventing deaths from all causes. The randomized, double-blind, placebo-controlled trial showed a 50% or greater reduction in influenza-related illness. Recent cost-effectiveness studies confirm the efficacy of influenza vaccine in reducing influenza-related morbidity and mortality and show that vaccine provides important cost savings per year per vaccinated person. Conclusion: Despite the paucity of randomized trials, many studies confirm that influenza vaccine reduces the risks for pneumonia, hospitalization, and death in elderly persons during an influenza epidemic if the vaccine strain is identical or similar to the epidemic strain. Influenza immunization is an indispensable part of the care of persons 65 years of age and older. Annual vaccine administration requires the attention of all physicians and public health organizations.
引用
收藏
页码:518 / 527
页数:10
相关论文
共 52 条
[1]   A STUDY OF EXCESS MORTALITY DURING INFLUENZA EPIDEMICS IN THE UNITED-STATES, 1968-1976 [J].
ALLING, DW ;
BLACKWELDER, WC ;
STUARTHARRIS, CH .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1981, 113 (01) :30-43
[2]   INFLUENZA A/PHILIPPINES/2/82 OUTBREAK IN A NURSING-HOME - LIMITATIONS OF INFLUENZA VACCINATION IN THE AGED [J].
ARROYO, JC ;
POSTIC, B ;
BROWN, A ;
HARRISON, K ;
BIRGENHEIER, R ;
DOWDA, H .
AMERICAN JOURNAL OF INFECTION CONTROL, 1984, 12 (06) :329-334
[3]  
Aymard M, 1979, Dev Biol Stand, V43, P231
[4]  
BARKER W, 1993, OPTIONS CONTROL INFL, V2, P143
[5]   INFLUENZA VACCINATION OF ELDERLY PERSONS - REDUCTION IN PNEUMONIA AND INFLUENZA HOSPITALIZATIONS AND DEATHS [J].
BARKER, WH ;
MULLOOLY, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1980, 244 (22) :2547-2549
[6]   THE STANDARDIZATION OF CRITERIA FOR PROCESSING AND INTERPRETING LABORATORY SPECIMENS IN PATIENTS WITH SUSPECTED VENTILATOR-ASSOCIATED PNEUMONIA [J].
BASELSKI, VS ;
ELTORKY, M ;
COALSON, JJ ;
GRIFFIN, JP .
CHEST, 1992, 102 (05) :S571-S579
[7]   ANTIBODY INDUCTION BY INFLUENZA VACCINES IN THE ELDERLY - A REVIEW OF THE LITERATURE [J].
BEYER, WEP ;
PALACHE, AM ;
BALJET, M ;
MASUREL, N .
VACCINE, 1989, 7 (05) :385-394
[8]  
CARTTER ML, 1990, INFECT CONT HOSP EP, V11, P473
[9]  
Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P601
[10]  
CURRIER M, 1988, MMJ (Maryland Medical Journal), V37, P781